A Phase 3 interventional study of dolutegravir 50 mg OAD and darunavir 800mg OAD in Infection, Human Immunodeficiency Virus, sponsored by ViiV Healthcare. Completed at 66 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-01-16.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will be conducted in approximately 468 HIV-1 infected antiretroviral therapy (ART)-naïve subjects. Subjects will be randomized 1:1 to receive dolutegravir (DTG) 50 mg once daily (approximately 234 subjects) or darunavir/ritonavir (DRV/r) 800 mg/100 mg once daily (approximately 234 subjects), each in combination with fixed-dose dual nucleoside reverse transriptase inhibitor (NRTI) therapy (either abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC). Subjects will be stratified by screening HIV-1 RNA and background NRTI selection. The primary analysis will take place after the last subject completes 48 weeks on therapy; an additional analysis will be conducted after the last subject completes Week 96 on study.
ING114915 is a Phase IIIb randomized, open-label, active-controlled, multicentre, parallel group, fully-powered non-inferiority study. The study will be conducted in approximately 468 HIV-1 infected ART-naïve subjects. Subjects will be randomized 1:1 to receive DTG 50 mg once daily (approximately 234 subjects) or DRV/r 800 mg/100 mg once daily (approximately 234 subjects), each in combination with fixed-dose dual NRTI therapy (either ABC/3TC or TDF/FTC). The primary analysis will take place after the last subject completes 48 weeks on therapy; an additional analysis will be conducted after the last subject completes Week 96 on study.
Subjects who fulfil eligibility requirements will be randomized 1:1 to receive DTG 50 mg once daily or DRV/r 800 mg/100 mg once daily. In order to achieve balance across the two treatment groups of the study, randomization will be stratified by: screening plasma HIV-1 RNA >/ 100,000 copies/mL (c/mL) or > 100,000 c/mL and background dual NRTI (ABC/3TC or TDF/FTC) The DTG and DRV/r doses will be administered in an open-label fashion throughout the study.
Subjects randomized to receive DTG and who successfully complete 96 weeks of treatment will continue to have access to DTG until either it is locally approved and commercially available, the patient no longer derives clinical benefit, the patient meets a protocol-defined reason for discontinuation or until development of DTG is terminated. Subjects randomized to the DRV/r arm will receive DRV/r through their Week 96 visit, after which they will be discontinued from the study and will need to make alternative arrangements to access antiretroviral medication. All subjects will receive background dual-NRTI therapy through their Week 96 visit.
2,096 studies on the registry are indexed under Infections; 364 are open to participants now.
This study's enrollment of 488 is above the median of 113 across 1,304 interventional studies indexed under Infections.
Browse Infections studies →ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
in combination with either abacavir/lamivudine fixed dose combination tablet OAD or tenofovir disoproxil fumarate/emtricitabline fixed dose combination tablet OAD
Drug: dolutegravir 50 mg OAD
in combination with either abacavir/lamivudine fixed dose combination tablet OAD or tenofovir disoproxil fumarate/emtricitabline fixed dose combination tablet OAD
Drug: darunavir 800mg OAD · Drug: ritonavir 100mg OAD
1 x 50 mg tablet OAD
2 x 400mg tablets OAD
1 x 100mg tablet OAD
Percentage of Participants With Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/Milliliter (c/mL) at Week 48
Assessment was done using Missing, Switch or Discontinuation = Failure (MSDF), as codified by the Food and Drug Administration (FDA) "snapshot" algorithm.This algorithm treated all participants without HIV-1 RNA data at Week 48 as nonresponders, as well as participants who switched their concomitant ART prior to Week 48 as follows: background ART substitutions non-permitted per protocol (one background ART substitution was permitted for safety or tolerability); background ART substitutions permitted per protocol unless the decision to switch was documented as being before or at the first on-treatment visit where HIV-1 RNA was assessed. Otherwise, virologic success or failure was determined by the last available HIV-1 RNA assessment while the participant was on-treatment in the snapshot window (Week 48 +/- 6 weeks). Modified Intent-To-Treat Exposed (mITT-E) Population:all randomized participants who received at least one dose of investigational product
Time frame: Week 48
Time to Virologic Suppression (<50 Copies/mL) Through Week 48
The time to viral suppression (i.e. first viral load value \<50 copies/mL) through Week 48 was derived and summarized using Kaplan-Meier plots. Participants who withdrew for any reason without having suppressed prior to the analysis were censored. Confidence intervals were estimated using the Brookmeyer-Crowley method.
Time frame: From Baseline through Week 48
Percentage of Participants With Plasma HIV-1 RNA <400 c/mL at Week 48
The percentage of participants with Plasma HIV-1 RNA \<400 c/mL at Week 48 was assessed MSDF, as codified by the FDA "snapshot" algorithm. This algorithm treated all participants without HIV-1 RNA data at Week 48 as nonresponders, as well as participants who switched their concomitant ART prior to Week 48 as follows: background ART substitutions non-permitted per protocol (one background ART substitution was permitted for safety or tolerability); background ART substitutions permitted per protocol unless the decision to switch was documented as being before or at the first on-treatment visit where HIV-1 RNA was assessed. Otherwise, virologic success or failure was determined by the last available HIV-1 RNA assessment while the participant was on-treatment in the snapshot window (Week 48 +/- 6 weeks).
Time frame: Week 48
Change From Baseline in Plasma HIV-1 RNA (log10 c/mL) at Weeks 4, 8, 12, 16, 24, 36 and 48
Change from Baseline in plasma HIV-1 RNA (log10 c/mL) was assessed at Weeks 4, 8, 12, 16, 24, 36 and 48 . Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different visits, so the overall number of participants analyzed reflects everyone in the mITT-E Population.
Time frame: Baseline, Weeks 4, 8, 12, 16, 24, 36 and 48
Change From Baseline in CD4+ and CD8+ Cell Counts
Change from Baseline in CD4+ cell counts was assessed at Weeks 4, 8, 12, 16, 36 and 48. Change from Baseline in CD8+ cell counts was assessed at Weeks 4, 12, 24 and 48. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different visits and parameters, so the overall number of participants analyzed reflects everyone in the mITT-E Population.
Time frame: Baseline and Weeks 4, 8, 12, 16, 36 and 48 for CD4+ and Baseline and Weeks 4, 12, 24 and 48 for CD8+
Number of Participants With HIV-1 Associated Disease Progression With the Indicated Shift to CDC Class C, or New CDC Class C or Death at Week 48
The number of participants with HIV-1 disease progression (AIDS or death) was assessed per the Centers for Disease Control and Prevention (CDC) 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. The CDC classifies HIV infection as Category A (participants with asymptomatic HIV infection, acute HIV infection with accompanying illness, or persistent generalized lymphadenopathy), Category B (participants with symptomatic non-AIDS condition, i.e., conditions that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or conditions are considered by physicians to have a clinical course or to require management that is complicated by HIV infection), and Category C (includes AIDS indicator conditions as defined by diagnostic or presumptive measures).
Time frame: Week 48
Change From Baseline in Fasting Low-density Lipoprotein (LDL) Cholesterol Through Week 48
Fasting LDL cholesterol change from Baseline was analyzed. Values represented are for adjusted means. Estimates are calculated from a repeated measures model including the following covariates: treatment, visit, Baseline plasma HIV-1 RNA, background dual NRTI therapy, Baseline LDL cholesterol, treatment\*visit interaction and Baseline LDL cholesterol\*visit interaction. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants with data available at the specified time points were analyzed.
Time frame: From Baseline through Week 48
Percentage of Participants With Grade 2 or Higher Abnormalities in Fasting LDL Cholesterol Through Week 48
Hematology and clinical chemistry data were summarized according to the division of AIDS (DAIDS) table for grading the Severity of adverse events, version 1.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for which an increase in fasting LDL cholesterol to Grade 2 or higher occurred. Only those participants with data available at the specified time points were analyzed.
Time frame: From Baseline through Week 48
Number of Participants With the Indicated Grade 3 and Grade 4 Maximum Post-Baseline Chemistry and Hematology Laboratory Toxicities
Hematology and clinical chemistry data were summarized according to the division of AIDS (DAIDS) table for grading the Severity of adverse events, version 1.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to Grade 3 or Grade 4 occurred.
Time frame: From Baseline through Week 48
Number of Participants (Par.) With Detectable Virus That Has Genotypic or Phenotypic Evidence of Treatment-emergent Resistance to DTG, DRV+RTV and Other On-study ART at Time of Protocol Defined Virology Failure (PDVF)
An assessment was made of every change across all amino acids within the integrase (IN), reverse transcriptase (RT), and Protease (PRO) encoding region at Baseline and at time of suspected PDVF. PDVF is defined as the confirmed plasma HIV-1 RNA \>200 c/mL \>=Week 24. PDVF Genotypic Population included all participants in the mITT-E population with available on-treatment genotypic resistance data, at time of PDVF. Only those participants with data available at the specified time points were analyzed.
Time frame: Baseline until PDVF up to Week 48
Change From Baseline in Acquired Immune Deficiency Syndrome (AIDS) Clinical Trials Group (ACTG) Symptom Distress Module (SDM) Bother Score at Week 4, Week 24, and Week 48
SDM is a 20-item self-reported measure that addresses the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment. Each item is rated from 0 to 4 where 0 (complete absence of symptom) and 4 (very bothersome symptom). Overall score calculated as the sum of the scores for each of the 20 items of the questionnaire and ranged from 0 (best health) and 80 (worst health). Values represented are for adjusted mean. Estimates are calculated from an ANCOVA model adjusting for age, sex, race, baseline viral load, background dual NRTI therapy and baseline symptom bother score. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. A positive change from Baseline indicates a decline in a participant's quality of life over that period.
Time frame: Baseline, Week 4, Week 24, and Week 48
Change From Baseline in European Quality of Life -5 Dimensions (EQ-5D) Utility Scores at Week 24 and Week 48
The EQ-5D is a 5-question quality of life instrument that provides a utility score and visual analogue scale score that describes the participants' health status. The primary reason for including the EQ-5D is to elicit utility values for potential cost-effectiveness analysis for submission to health technology assessment agencies. The EQ-5D total score ranges from 0 (worst health state) to 1 (perfect health state) and 1 reflects the best outcome. Values represented are for adjusted mean. Estimates are calculated from an ANCOVA model adjusting for age, sex, race, baseline viral load, background dual NRTI therapy and Baseline EQ-5D utility score. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Baseline, Week 24, and Week 48
Change From Baseline in EQ-5D Thermometer Scores at Week 24 and Week 48
The European Quality of Life -5 Dimensions (EQ-5D) is a 5-question quality of life instrument that provides a utility score and visual analogue scale score that describes the participants' health status. The primary reason for including the EQ-5D is to elicit utility values for potential cost-effectiveness analysis for submission to health technology assessment agencies. Thermometer score is based on a visual analogue scale (VAS) ranging from 100 (best imaginable health state) to 0 (worst imaginable health state).Values represented are for adjusted mean. Estimates are calculated from an ANCOVA model adjusting for age, sex, race, Baseline viral load, background dual NRTI therapy and Baseline EQ-5D thermometer score. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Baseline, Week 24, and Week 48
Human Immunodeficiency Virus Treatment Satisfaction Questionnaire (HIVTSQ) Total Score at Week 4, Week 24, and Week 48
Participant treatment satisfaction was measured using the self-reported scale (HIVTSQ), which consists of 10 items (1-satisfaction, 2-HIV control, 3-adverse effects, 4-level of demand, 5-convenience, 6-flexibility, 7-knowledge, 8-life habits, 9-recommendability, and 10-willingness to continue). Items are scored from 0 (very dissatisfied) to 6 (very satisfied), other than item 4, which has an inverted score from 6 (very demanding) to 0 (very undemanding). The treatment satisfaction score (range: 0-60) was the sum of the individual items. HIVTSQ mITT-E Population=Only participants from USA, France, Germany, Italy, Spain for whom valid translations were available from the mITT-E Population. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different visits, so the overall number of participants analyzed reflects everyone in the HIVTSQ mITT-E population.
Time frame: Week 4, Week 24, and Week 48
Human Immunodeficiency Virus Treatment Satisfaction Questionnaire (HIVTSQ) Lifestyle/Ease Sub Score at Week 4, Week 24, and Week 48
Participant treatment satisfaction was measured using the self-reported scale (HIVTSQ), which consists of 10 items (1-satisfaction, 2-HIV control, 3-adverse effects, 4-level of demand, 5-convenience, 6-flexibility, 7-knowledge, 8-life habits, 9-recommendability, and 10-willingness to continue). Items are scored from 0 (very dissatisfied) to 6 (very satisfied), other than item 4, which has an inverted score from 6 (very demanding) to 0 (very undemanding). The lifestyle/ease score is the sum of items 4, 5, 6, 7 and 8 (range: 0-30). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different visits, so the overall number of participants analyzed reflects everyone in the HIVTSQ mITT-E population.
Time frame: Week 4, Week 24, and Week 48
Human Immunodeficiency Virus Treatment Satisfaction Questionnaire (HIVTSQ) Convenience Score at Week 4, Week 24, and Week 48
Participant treatment satisfaction was measured using the self-reported scale (HIVTSQ), which consists of 10 items (1-satisfaction, 2-HIV control, 3-adverse effects, 4-level of demand, 5-convenience, 6-flexibility, 7-knowledge, 8-life habits, 9-recommendability, and 10-willingness to continue). Items are scored from 0 (very dissatisfied) to 6 (very satisfied), other than item 4, which has an inverted score from 6 (very demanding) to 0 (very undemanding). The convenience score is the score for item 5 (range: 0-6). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different visits, so the overall number of participants analyzed reflects everyone in the HIVTSQ mITT-E population.
Time frame: Week 4, Week 24, and Week 48
This was a 2 sequential treatment period study. In first period (Randomization phase) participants received either dolutegravir (DTG) 50 milligram (mg) or darunavir (DRV) 800 mg with ritonavir (RTV) 100 mg once daily (QD) for 96 weeks. DTG participants who completed 96 Weeks of DTG then continued to receive DTG 50 mg in Extension phase.
| Milestone | DTG 50 mg QD | DRV 800 mg + RTV 100 mg QD | Extension DTG 50 mg |
|---|---|---|---|
| Started | 242 | 242 | 0 |
| Completed | 209 | 189 | 0 |
| Not completed | 33 | 53 | 0 |
| Withdrew: Adverse event | 5 | 13 | 0 |
| Withdrew: Lack of efficacy | 3 | 4 | 0 |
| Withdrew: Protocol violation | 5 | 6 | 0 |
| Withdrew: Protocol-defined stopping criteria | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 15 | 18 | 0 |
| Withdrew: Withdrawal by subject | 2 | 8 | 0 |
| Withdrew: Physician decision | 2 | 3 | 0 |
| Withdrew: Other: study closed/terminated | 0 | 1 | 0 |
| Milestone | DTG 50 mg QD | DRV 800 mg + RTV 100 mg QD | Extension DTG 50 mg |
|---|---|---|---|
| Started | 0 | 0 | 123 |
| Completed | 0 | 0 | 115 |
| Not completed | 0 | 0 | 8 |
| Withdrew: Adverse event | 0 | 0 | 2 |
| Withdrew: Lack of efficacy | 0 | 0 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 4 |
Assessment was done using Missing, Switch or Discontinuation = Failure (MSDF), as codified by the Food and Drug Administration (FDA) "snapshot" algorithm.This algorithm treated all participants without HIV-1 RNA data at Week 48 as nonresponders, as well as participants who switched their concomitant ART prior to Week 48 as follows: background ART substitutions non-permitted per protocol (one background ART substitution was permitted for safety or tolerability); background ART substitutions permitted per protocol unless the decision to switch was documented as being before or at the first on-treatment visit where HIV-1 RNA was assessed. Otherwise, virologic success or failure was determined by the last available HIV-1 RNA assessment while the participant was on-treatment in the snapshot window (Week 48 +/- 6 weeks). Modified Intent-To-Treat Exposed (mITT-E) Population:all randomized participants who received at least one dose of investigational product
| Percentage of participants | DTG 50 mg QD | DRV 800 mg + RTV 100 mg QD |
|---|---|---|
| Percentage of Participants With Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/Milliliter (c/mL) at Week 48 | 90 | 83 |
The time to viral suppression (i.e. first viral load value \<50 copies/mL) through Week 48 was derived and summarized using Kaplan-Meier plots. Participants who withdrew for any reason without having suppressed prior to the analysis were censored. Confidence intervals were estimated using the Brookmeyer-Crowley method.
| Days | DTG 50 mg QD | DRV 800 mg + RTV 100 mg QD |
|---|---|---|
| Time to Virologic Suppression (<50 Copies/mL) Through Week 48 | 28.0 (NA to NA) | 85.0 (84.0 to 108.0) |
The percentage of participants with Plasma HIV-1 RNA \<400 c/mL at Week 48 was assessed MSDF, as codified by the FDA "snapshot" algorithm. This algorithm treated all participants without HIV-1 RNA data at Week 48 as nonresponders, as well as participants who switched their concomitant ART prior to Week 48 as follows: background ART substitutions non-permitted per protocol (one background ART substitution was permitted for safety or tolerability); background ART substitutions permitted per protocol unless the decision to switch was documented as being before or at the first on-treatment visit where HIV-1 RNA was assessed. Otherwise, virologic success or failure was determined by the last available HIV-1 RNA assessment while the participant was on-treatment in the snapshot window (Week 48 +/- 6 weeks).
| Percentage of participants | DTG 50 mg QD | DRV 800 mg + RTV 100 mg QD |
|---|---|---|
| Percentage of Participants With Plasma HIV-1 RNA <400 c/mL at Week 48 | 92 | 87 |
Change from Baseline in plasma HIV-1 RNA (log10 c/mL) was assessed at Weeks 4, 8, 12, 16, 24, 36 and 48 . Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different visits, so the overall number of participants analyzed reflects everyone in the mITT-E Population.
| Log10 copies per mL | DTG 50 mg OD | DRV 800 mg + RTV 100 mg OD |
|---|---|---|
| Week 4, n=238, 235 | -2.80 ± 0.625 | -2.01 ± 0.454 |
| Week 8, n=237, 236 | -2.86 ± 0.649 | -2.40 ± 0.524 |
| Week 12, n=234, 227 | -2.88 ± 0.653 | -2.61 ± 0.537 |
| Week 16, n=229, 228 | -2.86 ± 0.691 | -2.71 ± 0.618 |
| Week 24, n=234, 227 | -2.86 ± 0.765 | -2.83 ± 0.663 |
| Week 36, n=232, 218 | -2.87 ± 0.715 | -2.85 ± 0.683 |
| Week 48, n=227, 212 | -2.89 ± 0.739 | -2.86 ± 0.663 |
Change from Baseline in CD4+ cell counts was assessed at Weeks 4, 8, 12, 16, 36 and 48. Change from Baseline in CD8+ cell counts was assessed at Weeks 4, 12, 24 and 48. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different visits and parameters, so the overall number of participants analyzed reflects everyone in the mITT-E Population.
| Cells per millimeters cubed (cells/mm^3) | DTG 50 mg QD | DRV 800 mg + RTV 100 mg QD |
|---|---|---|
| CD4+ cell count, Week 4, n=237, 236 | 80.1 ± 101.36 | 75.6 ± 124.36 |
| CD4+ cell count, Week 8, n=236, 236 | 126.9 ± 124.13 | 118.8 ± 142.54 |
| CD4+ cell count, Week 12, n=234, 228 | 135.2 ± 120.03 | 131.8 ± 143.88 |
| CD4+ cell count, Week 16, n=227, 227 | 156.8 ± 146.60 | 146.1 ± 166.08 |
| CD4+ cell count, Week 24, n=233, 227 | 165.1 ± 145.85 | 164.3 ± 180.00 |
| CD4+ cell count, Week 36, n=232, 218 | 206.1 ± 159.06 | 186.5 ± 183.61 |
| CD4+ cell count, Week 48, n=227, 212 | 243.8 ± 180.68 | 215.4 ± 177.26 |
| CD8+ cell count, Week 4, n=235, 235 | -47.4 ± 276.01 | -3.7 ± 375.94 |
| CD8+ cell count, Week 12, n=231, 227 | -42.0 ± 343.81 | -68.9 ± 373.38 |
| CD8+ cell count, Week 24, n=231, 224 | -108.0 ± 350.03 | -132.9 ± 389.70 |
| CD8+ cell count, Week 48, n=224, 210 | -109.5 ± 360.94 | -162.1 ± 421.07 |
The number of participants with HIV-1 disease progression (AIDS or death) was assessed per the Centers for Disease Control and Prevention (CDC) 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. The CDC classifies HIV infection as Category A (participants with asymptomatic HIV infection, acute HIV infection with accompanying illness, or persistent generalized lymphadenopathy), Category B (participants with symptomatic non-AIDS condition, i.e., conditions that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or conditions are considered by physicians to have a clinical course or to require management that is complicated by HIV infection), and Category C (includes AIDS indicator conditions as defined by diagnostic or presumptive measures).
| Participants | DTG 50 mg QD | DRV 800 mg + RTV 100 mg QD |
|---|---|---|
| Number of Participants With HIV-1 Associated Disease Progression With the Indicated Shift to CDC Class C, or New CDC Class C or Death at Week 48 | 0 | 0 |
Fasting LDL cholesterol change from Baseline was analyzed. Values represented are for adjusted means. Estimates are calculated from a repeated measures model including the following covariates: treatment, visit, Baseline plasma HIV-1 RNA, background dual NRTI therapy, Baseline LDL cholesterol, treatment\*visit interaction and Baseline LDL cholesterol\*visit interaction. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants with data available at the specified time points were analyzed.
| Millimoles per liter (mmol/L) | DTG 50 mg QD | DRV 800 mg + RTV 100 mg QD |
|---|---|---|
| Change From Baseline in Fasting Low-density Lipoprotein (LDL) Cholesterol Through Week 48 | 0.07 ± 0.041 | 0.37 ± 0.041 |
Hematology and clinical chemistry data were summarized according to the division of AIDS (DAIDS) table for grading the Severity of adverse events, version 1.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for which an increase in fasting LDL cholesterol to Grade 2 or higher occurred. Only those participants with data available at the specified time points were analyzed.
| Percentage of Participants | DTG 50 mg QD | DRV 800 mg + RTV 100 mg QD |
|---|---|---|
| Percentage of Participants With Grade 2 or Higher Abnormalities in Fasting LDL Cholesterol Through Week 48 | 2 | 7 |
Hematology and clinical chemistry data were summarized according to the division of AIDS (DAIDS) table for grading the Severity of adverse events, version 1.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to Grade 3 or Grade 4 occurred.
| Participants | DTG 50 mg QD | DRV 800 mg + RTV 100 mg QD |
|---|---|---|
| Alanine Amino Transferase, G3 | 2 | 1 |
| Alanine Amino Transferase, G4 | 1 | 3 |
| Aspartate Amino Transferase, G3 | 6 | 3 |
| Aspartate Amino Transferase, G4 | 2 | 0 |
| Cholesterol, G3 | 0 | 3 |
| Creatine Kinase, G3 | 8 | 5 |
| Creatine Kinase, G4 | 8 | 4 |
| Hyperglycaemia, G3 | 1 | 2 |
| Hypoglycaemia, G3 | 0 | 1 |
| LDL Cholesterol, G3 | 2 | 6 |
| Lipase, G3 | 5 | 5 |
| Lipase, G4 | 2 | 0 |
| Phosphorus, inorganic, G3 | 7 | 7 |
| Total Bilirubin, G3 | 1 | 0 |
| Triglycerides, G3 | 1 | 2 |
| Triglycerides, G4 | 0 | 1 |
| Hemoglobin, G3 | 1 | 0 |
| Hemoglobin, G4 | 1 | 0 |
| Platelet count, G4 | 0 | 1 |
| Total Neutrophils, G3 | 5 | 0 |
| Total Neutrophils, G4 | 3 | 1 |
An assessment was made of every change across all amino acids within the integrase (IN), reverse transcriptase (RT), and Protease (PRO) encoding region at Baseline and at time of suspected PDVF. PDVF is defined as the confirmed plasma HIV-1 RNA \>200 c/mL \>=Week 24. PDVF Genotypic Population included all participants in the mITT-E population with available on-treatment genotypic resistance data, at time of PDVF. Only those participants with data available at the specified time points were analyzed.
| Participants | DTG 50 mg OD | DRV 800 mg + RTV 100 mg OD |
|---|---|---|
| Number of Participants (Par.) With Detectable Virus That Has Genotypic or Phenotypic Evidence of Treatment-emergent Resistance to DTG, DRV+RTV and Other On-study ART at Time of Protocol Defined Virology Failure (PDVF) | 0 | 0 |
SDM is a 20-item self-reported measure that addresses the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment. Each item is rated from 0 to 4 where 0 (complete absence of symptom) and 4 (very bothersome symptom). Overall score calculated as the sum of the scores for each of the 20 items of the questionnaire and ranged from 0 (best health) and 80 (worst health). Values represented are for adjusted mean. Estimates are calculated from an ANCOVA model adjusting for age, sex, race, baseline viral load, background dual NRTI therapy and baseline symptom bother score. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. A positive change from Baseline indicates a decline in a participant's quality of life over that period.
| Scores on a scale | DTG 50 mg QD | DRV 800 mg + RTV 100 mg QD |
|---|---|---|
| Week 4, n=218, 210 | -3.20 ± 0.56 | -2.19 ± 0.56 |
| Week 24, n=222, 214 | -2.71 ± 0.64 | -1.65 ± 0.65 |
| Week 48, n= 222, 215 | -2.46 ± 0.68 | -0.77 ± 0.69 |
The EQ-5D is a 5-question quality of life instrument that provides a utility score and visual analogue scale score that describes the participants' health status. The primary reason for including the EQ-5D is to elicit utility values for potential cost-effectiveness analysis for submission to health technology assessment agencies. The EQ-5D total score ranges from 0 (worst health state) to 1 (perfect health state) and 1 reflects the best outcome. Values represented are for adjusted mean. Estimates are calculated from an ANCOVA model adjusting for age, sex, race, baseline viral load, background dual NRTI therapy and Baseline EQ-5D utility score. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
| Scores on a scale | DTG 50 mg QD | DRV 800 mg + RTV 100 mg QD |
|---|---|---|
| Week 24, n=217, 213 | 0.00 ± 0.012 | 0.02 ± 0.012 |
| Week 48, n=224, 217 | 0.01 ± 0.012 | 0.01 ± 0.012 |
The European Quality of Life -5 Dimensions (EQ-5D) is a 5-question quality of life instrument that provides a utility score and visual analogue scale score that describes the participants' health status. The primary reason for including the EQ-5D is to elicit utility values for potential cost-effectiveness analysis for submission to health technology assessment agencies. Thermometer score is based on a visual analogue scale (VAS) ranging from 100 (best imaginable health state) to 0 (worst imaginable health state).Values represented are for adjusted mean. Estimates are calculated from an ANCOVA model adjusting for age, sex, race, Baseline viral load, background dual NRTI therapy and Baseline EQ-5D thermometer score. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
| Scores on a scale | DTG 50 mg QD | DRV 800 mg + RTV 100 mg QD |
|---|---|---|
| Week 24, n=221, 216 | 4.95 ± 0.885 | 5.96 ± 0.895 |
| Week 48, n=224, 220 | 5.78 ± 0.762 | 6.95 ± 0.769 |
Participant treatment satisfaction was measured using the self-reported scale (HIVTSQ), which consists of 10 items (1-satisfaction, 2-HIV control, 3-adverse effects, 4-level of demand, 5-convenience, 6-flexibility, 7-knowledge, 8-life habits, 9-recommendability, and 10-willingness to continue). Items are scored from 0 (very dissatisfied) to 6 (very satisfied), other than item 4, which has an inverted score from 6 (very demanding) to 0 (very undemanding). The treatment satisfaction score (range: 0-60) was the sum of the individual items. HIVTSQ mITT-E Population=Only participants from USA, France, Germany, Italy, Spain for whom valid translations were available from the mITT-E Population. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different visits, so the overall number of participants analyzed reflects everyone in the HIVTSQ mITT-E population.
| Scores on a scale | DTG 50 mg QD | DRV 800 mg + RTV 100 mg QD |
|---|---|---|
| Week 4, n=206, 192 | 54.1 ± 6.43 | 52.4 ± 7.94 |
| Week 24, n= 211, 200 | 56.1 ± 5.16 | 54.3 ± 6.94 |
| Week 48, n=212, 201 | 56.1 ± 4.60 | 54.5 ± 6.78 |
Participant treatment satisfaction was measured using the self-reported scale (HIVTSQ), which consists of 10 items (1-satisfaction, 2-HIV control, 3-adverse effects, 4-level of demand, 5-convenience, 6-flexibility, 7-knowledge, 8-life habits, 9-recommendability, and 10-willingness to continue). Items are scored from 0 (very dissatisfied) to 6 (very satisfied), other than item 4, which has an inverted score from 6 (very demanding) to 0 (very undemanding). The lifestyle/ease score is the sum of items 4, 5, 6, 7 and 8 (range: 0-30). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different visits, so the overall number of participants analyzed reflects everyone in the HIVTSQ mITT-E population.
| Scores on a scale | DTG 50 mg QD | DRV 800 mg + RTV 100 mg QD |
|---|---|---|
| Week 4, n=202, 190 | 26.7 ± 3.61 | 25.8 ± 4.48 |
| Week 24, n=210, 199 | 27.5 ± 3.16 | 26.6 ± 4.11 |
| Week 48, n=211, 201 | 27.6 ± 3.00 | 26.6 ± 4.11 |
Participant treatment satisfaction was measured using the self-reported scale (HIVTSQ), which consists of 10 items (1-satisfaction, 2-HIV control, 3-adverse effects, 4-level of demand, 5-convenience, 6-flexibility, 7-knowledge, 8-life habits, 9-recommendability, and 10-willingness to continue). Items are scored from 0 (very dissatisfied) to 6 (very satisfied), other than item 4, which has an inverted score from 6 (very demanding) to 0 (very undemanding). The convenience score is the score for item 5 (range: 0-6). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different visits, so the overall number of participants analyzed reflects everyone in the HIVTSQ mITT-E population.
| Scores on a scale | DTG 50 mg QD | DRV 800 mg + RTV 100 mg QD |
|---|---|---|
| Week 4, n=204, 190 | 5.6 ± 0.71 | 5.2 ± 1.11 |
| Week 24, n=211, 200, | 5.6 ± 0.64 | 5.4 ± 1.01 |
| Week 48, n=212, 201 | 5.7 ± 0.62 | 5.4 ± 1.02 |
Collected over Serious adverse events (SAEs) and non-serious adverse events (AEs) are presented from the available safety data from the start of the study medication up to end of study.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DTG 50mg QD | 1/242 (0.4%) | 36/242 (14.9%) | 221/242 (91.3%) |
| DRV 800 mg + RTV 100 mg QD | 0/242 (0%) | 21/242 (8.7%) | 214/242 (88.4%) |
| Extension DTG 50 mg | 0/123 (0%) | 4/123 (3.3%) | 52/123 (42.3%) |
| Event | DTG 50mg QD | DRV 800 mg + RTV 100 mg QD | Extension DTG 50 mg |
|---|---|---|---|
| Suicide attemptPsychiatric disorders | 3/242 | 0/242 | 1/123 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 2/242 | 0/242 | 0/123 |
| Back injuryInjury, poisoning and procedural complications | 0/242 | 0/242 | 1/123 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/242 | 0/242 | 1/123 |
| MethaemoglobinaemiaBlood and lymphatic system disorders | 0/242 | 0/242 | 1/123 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 1/242 | 1/242 | 0/123 |
| Acute hepatitis CInfections and infestations | 1/242 | 1/242 | 0/123 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/242 | 1/242 | 0/123 |
| DepressionPsychiatric disorders | 1/242 | 1/242 | 0/123 |
| Abdominal adhesionsGastrointestinal disorders | 1/242 | 0/242 | 0/123 |
| Event | DTG 50mg QD | DRV 800 mg + RTV 100 mg QD | Extension DTG 50 mg |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 43/242 | 74/242 | 2/123 |
| NauseaGastrointestinal disorders | 40/242 | 48/242 | 2/123 |
| HeadacheNervous system disorders | 40/242 | 26/242 | 2/123 |
| Upper respiratory tract infectionInfections and infestations | 16/242 | 27/242 | 1/123 |
| Viral upper respiratory tract infectionInfections and infestations | 26/242 | 24/242 | 5/123 |
| CoughRespiratory, thoracic and mediastinal disorders | 18/242 | 19/242 | 1/123 |
| InsomniaPsychiatric disorders | 19/242 | 16/242 | 1/123 |
| VomitingGastrointestinal disorders | 15/242 | 17/242 | 0/123 |
| Back painMusculoskeletal and connective tissue disorders | 14/242 | 17/242 | 0/123 |
| RashSkin and subcutaneous tissue disorders | 13/242 | 17/242 | 0/123 |
| Age, Continuous(Years) | DTG 50 mg QD | DRV 800 mg + RTV 100 mg QD | Total |
|---|---|---|---|
| Mean | 35.7 ± 10.66 | 36.2 ± 10.64 | 35.9 ± 10.64 |
| Sex: Female, Male(Participants) | DTG 50 mg QD | DRV 800 mg + RTV 100 mg QD | Total |
|---|---|---|---|
| Female | 31 | 41 | 72 |
| Male | 211 | 201 | 412 |
| Race/Ethnicity, Customized(Participants) | DTG 50 mg QD | DRV 800 mg + RTV 100 mg QD | Total |
|---|---|---|---|
| African American/African Heritage | 60 | 53 | 113 |
| American Indian or Alaska Native | 3 | 9 | 12 |
| Asian - Central/South Asian Heritage | 0 | 1 | 1 |
| Asian - Japanese Heritage | 1 | 0 | 1 |
| Asian - South East Asian Heritage | 1 | 0 | 1 |
| Native Hawaiian or other Pacific Islander | 2 | 0 | 2 |
| White - Arabic/North African Heritage | 4 | 3 | 7 |
| White - White/Caucasian/European Heritage | 169 | 173 | 342 |
| Mixed Race | 1 | 3 | 4 |
| Missing | 1 | 0 | 1 |
Ran from Oct 2011 to primary completion in Apr 2013, 17 months.
Results were first posted in Mar 2014, 11 months after primary completion.
Of 41 industry-sponsored phase 3 interventional studies under Infections, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 33. This study's 17 months is below that.
Counting every sponsor, half of 75 studies reached it within 30 months; a quarter within 17 and three quarters within 53.
Infections covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dolutegravir